Poland· PL-100255932

Envil gardło

A cetylpyridinium product containing cetylpyridini chloridum +lidocaini hydrochloridum monohydricum + zinci gluconas, registered in Poland by Aflofarm Farmacja Polska Sp. z o.o.. The same ATC class is registered in 4 of our 19 countries.

ATC R02AA06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedEnvil gardłoATCR02AA06REGISTER NO.PL-100255932PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Cetylpyridinium is registered in 4 of 19 countries.

Countries holding a registration under ATC R02AA06 (cetylpyridinium), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose

Cetylpyridinium · ATC R02AA06

4 / 19 countries

  • Canada
  • Czechiaprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Cetylpyridini chloridum +Lidocaini hydrochloridum monohydricum + Zinci gluconas
Manufacturer
Aflofarm Farmacja Polska Sp. z o.o.
Country
Poland (PL)
ATC code
R02AA06
ATC class
Cetylpyridinium
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909990906703
  • gtin
    05909990906734
  • gtin
    05902802700209

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for cetylpyridinium.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cetylpyridinium · interactions on record

1 record

  • 1 moderate

Most severe, free to view

  • Hyaluronic acidM09AX01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bd2345b3-afe3-4451-b0b8-f55830be4454
GET /v1/drugs/bd2345b3-afe3-4451-b0b8-f55830be4454?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki do ssania",
  "source": "urpl",
  "strength": "1,5 mg + 1 mg + 17,42 mg",
  "packaging": "05909990906703 ¦ OTC ¦ 69841\n10 tabl.\n05909990906734 ¦ OTC ¦ 69842\n20 tabl.\n05902802700209 ¦ OTC ¦ 128573\n60 tabl.",
  "substance": "Cetylpyridinii chloridum 1.5 mg + Lidocaini hydrochloridum monohydricum 1 mg + Zinci gluconas 17.42 mg",
  "common_name": "Cetylpyridini chloridum +Lidocaini hydrochloridum monohydricum + Zinci gluconas",
  "pl_product_id": "100255932",
  "pozwolenie_nr": "18687",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about cetylpyridinium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.